Seagen Inc.(SGEN) Stock Research - Grey Stern Research

Seagen Inc. (SGEN) Stock Analysis

$228.74 (-0.07%)

SGEN Financial Performance


Use the table below to view Seagen Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2023

Metric Value Ranking among Peers
Price $228.74 -
52 Week Low $126.47 -
52 Week High $228.96 -
Market Cap $43.2 Billion 1/19
Gross Margin 75% 11/19
Profit Margin -33% 14/19
EBITDA margin -34% 9/19
Q3 - 2023 Revenue $648.7 Million 5/19
Q3 - 2023 Earnings -$215.8 Million 17/19
Q3 - 2023 Free Cash Flow -$79.8 Million 16/19
Trailing 4 Quarters Revenue $2.3 Billion 5/19
Trailing 4 Quarters Earnings -$750.2 Million 18/19
Quarterly Earnings Growth -13% 11/19
Annual Earnings Growth -26% 12/19
Quarterly Revenue Growth 27% 9/19
Annual Revenue Growth 15% 11/19
Cash On Hand $428.6 Million 11/19
Short Term Debt $0 18/19
Long Term Debt $113.5 Million 9/19

Seagen Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Seagen Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 8/19
PS 18.76 5/19
PB 16.92 3/19
PC 100.70 2/19
Liabilities to Equity 0.42 9/19
ROA -0.21 12/19
ROE -0.29 12/19
Current Ratio 3.35 9/19
Quick Ratio 1.14 11/19
Long Term Debt to Equity 0.04 10/19
Debt to Equity 0.04 12/19
Burn Rate 1.95 13/19
Cash to Cap 0.01 18/19
CCR 0.37 13/19
EV to EBITDA -191.83 18/19
EV to Revenue 18.62 5/19

Company Details

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

CEO: Dr. Clay Siegall

Website: https://www.seagen.com

Address: 21823 30th Dr SE Bothell, WASHINGTON

Exchange: NASDAQ Global Select

Industry: Biotechnology

Seagen Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Seagen Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Alnylam Pharmaceuticals, Inc. ALNY $35.5 Billion
BioMarin Pharmaceutical Inc. BMRN $13.6 Billion
Exelixis, Inc. EXEL $7.7 Billion
Halozyme Therapeutics, Inc. HALO $7.5 Billion
Viking Therapeutics, Inc. VKTX $7.6 Billion
Incyte Corporation INCY $12.9 Billion
TG Therapeutics, Inc. TGTX $3.9 Billion
Ultragenyx Pharmaceutical Inc. RARE $5.4 Billion
Madrigal Pharmaceuticals, Inc. MDGL $5.3 Billion
United Therapeutics Corporation UTHR $15.6 Billion
Apellis Pharmaceuticals, Inc. APLS $4.5 Billion
Zai Lab Limited ZLAB $2.1 Billion
Ascendis Pharma A/S ASND $8.8 Billion
IVERIC bio, Inc. ISEE $5.5 Billion
PDS Biotechnology Corporation PDSB $118.2 Million
X4 Pharmaceuticals, Inc. XFOR $119.2 Million
Immunovant, Inc. IMVT $4.3 Billion
Legend Biotech Corporation LEGN $9.3 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
SGEN Income Statements
Quarter Year Revenue Earnings
Q3 2023 $ 648.7 Million -$215.8 Million
Q2 2023 $ 603.8 Million -$211.5 Million
Q1 2023 $ 519.7 Million -$174.7 Million
Q4 2022 $ 528.2 Million -$148.2 Million
Q3 2022 $ 510.3 Million -$190.8 Million
Q2 2022 $ 497.5 Million -$134.8 Million
Q1 2022 $ 426.5 Million -$136.5 Million
Q4 2021 $ 429.9 Million -$174.6 Million

View All

SGEN Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2023 $428.6 Million $3.6 Billion $113.5 Million $2.6 Billion
Q2 2023 $308.4 Million $3.5 Billion $97.2 Million $2.6 Billion
Q1 2023 $335.8 Million $3.5 Billion $91.1 Million $2.7 Billion
Q4 2022 $319.9 Million $3.7 Billion $43.5 Million $2.8 Billion
Q3 2022 $362.6 Million $3.6 Billion $46.7 Million $2.8 Billion
Q2 2022 $364.9 Million $3.6 Billion $50.2 Million $2.9 Billion
Q1 2022 $261.0 Million $3.6 Billion $53.6 Million $3.0 Billion
Q4 2021 $424.8 Million $3.7 Billion $0 $3.6 Billion

View All

SGEN Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2023 -$79.8 Million -$43.9 Million $119.9 Million
Q2 2023 $0 $0 $0
Q1 2023 -$288.3 Million -$38.7 Million $13.6 Million
Q4 2022 -$108.7 Million -$29.2 Million -$44.9 Million
Q3 2022 -$335.9 Million -$33.3 Million -$6.5 Million
Q2 2022 -$86.5 Million -$14.8 Million $113.8 Million
Q1 2022 -$234.2 Million -$17.4 Million -$163.8 Million
Q4 2021 -$297.0 Million -$13.6 Million -$260.3 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions